Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

MedAlert Tag: Kratom

FDA Takes Steps to Restrict Certain Kratom Products

July 29, 2025

The FDA is recommending a rescheduling of certain 7-hydroxymitragynine (7-OH) kratom products under the Controlled Substances Act (CSA). Consumer kratom product that can be purchased in cafes, gas stations and online. The FDA’s new recommendation is specifically targeting 7-OH, a concentrated byproduct of the kratom plant; it is not focused on natural kratom leaf products. 7-OH is increasingly recognized as having potential for abuse because of its ability to bind to opioid receptors. The FDA found that 7-OH compounds typically only makes up a 1.6%-2% constituent of kratom leaves, and these 7-OH products likely involve chemical synthetic steps by producers, as some products saw 7-OH levels at 109-509% higher than expected at natural levels. The FDA also issued warning letters to seven companies for illegally distributing products containing 7-OH, including tablets, gummies, drink mixes and shots. Furthermore, the FDA is also issuing letters to health care professionals and is warning consumers about the risks associated with 7-OH products.

Read More
lockenvelopephone-handsetmagnifiermenucross-circle